Minimum dose of hCG to trigger final oocyte maturation and prevent OHSS in a long GnRHa protocol

Abstract

This paper was aimed to study the minimum dose of human chorionic gonadotropin (hCG) to effectively trigger maturation of oocytes and prevent ovarian hyperstimulation syndrome (OHSS) in a series of hyper-responders treated with a long gonadotropin releasing hormone agonist (GnRHa) protocol. Six women at high risk of developing severe OHSS in a long GnRHa protocol were enrolled into this study. Serum hormone levels on the day of and after hCG administration, antral follicle count, oocyte retrieval number and quality were determined. In total, 6 women aged between 29 and 36 years and at risk of developing severe OHSS, received 2000 U hCG. Five of them were treated with coasting for 1 day and the rest one for 4 days. The mean number of oocytes collected was 19 (range 14–27) and the fertilization rate per collected oocyte was 72.81%. Of the 6 women in the study, only one cancelled embryos transfer and all embryos were frozen, and then she delivered two health boys on term in the subsequent frozen-thawed embryo transfer (FET) cycle. Pregnancies and births were achieved in 3 patients out of 5 in vitro fertilization-embryo transfer (IVF-ET) cycles. No woman developed moderate or severe OHSS. Triggering with 2000 U hCG is feasible to prevent OHSS in unpredicted hyper-responders undergoing IVF in a long GnRHa protocol.

Keywords

human chorionic gonadotropin / ovarian hyperstimulation syndrome / in vitro fertilization

References

[1] HumaidanP., QuartaroloJ., PapanikolaouE.G.. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril, 2010, 94(2): 389-400

[2] FormanR.G., FrydmanR., EganD., et al.. Severe ovarian hyperstimulation syndrome using agonist of gonadotropin-releasing hormone for in vitro fertilization: a European series and a proposal for prevention. Fertil Steril, 1990, 53(3): 502-509

[3] Garcia-VelascoJ.A., IsazaV., QueaG., et al.. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing?. Fertil Steril, 2006, 85(3): 547-554

[4] AbdallaH.I., Ah-MoyeM., BrinsdenP., et al.. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil Steril, 1987, 48(6): 958-963

[5] NargundG., HutchisonL., ScaramuzziR., et al.. Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles. Reprod Biomed Online, 2007, 14(6): 682-685

[6] SpitzerD., WogatzkyJ., MurtingerM., et al.. Dopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome. Fertil Steril, 2011, 95(8): 2742-4.e1

[7] Youssef MAFM, Al-Inany HG, Evers JLH, et al. Intravenous fluids for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev, 2011,(2):CD001302

[8] VillasanteA., PachecoA., RuizA., et al.. Vascular endothelial cadherin regulates vascular permeability: implications for ovarian hyperstimulation syndrome. J Clin Endocrinol Metab, 2007, 92(1): 314-321

[9] LudwigM., DoodyK.J., DoodyK.M.. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril, 2003, 79(5): 1051-1059

[10] SchmidtD.W., MaierD.B., NulsenJ.C., et al.. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization. Fertil Steril, 2004, 82(4): 841-846

[11] UlugU., BahceciM., ErdenH.F., et al.. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod, 2002, 17(2): 310-313

[12] MoonH.S., JooB.S., MoonS.E., et al.. Short coasting of 1 or 2 days by withholding both gonadotropin and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Fertil Steril, 2008, 90(6): 2172

[13] YilmazN., UygurD., OzguE., et al.. Does coasting, a procedure to avoid ovarian hyperstimulation syndrome, affect assisted reproduction cycle outcome?. Fertil Steril, 2010, 94(1): 189-193